Biomea Fusion Inc
BMEA1.596USD
+0.026+1.66%
交易中 （美东）报价延迟15分钟
59.97M总市值
亏损市盈率 TTM
关于 Biomea Fusion Inc 公司
Biomea Fusion, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现和开发口服共价小分子，用于治疗患有代谢疾病和基因定义的癌症的患者。共价小分子是一种合成化合物，可与其靶蛋白形成永久键。该公司正在利用其专有的 FUSION 系统发现、设计和开发一系列共价结合小分子药物，旨在最大限度地为患者带来临床益处。其主要候选产品 BMF-219 旨在成为一种口服、强效且选择性的脑膜炎共价抑制剂，由其 FUSION 系统构建而成。该公司正在开发 BMF-219 用于治疗脑膜炎调节或依赖性疾病，例如 1 型和 2 型糖尿病以及液体和实体肿瘤的亚型。其第二个开发候选产品 BMF-500 是一种 FMS 样酪氨酸激酶 3 (FLT3) 激活突变的共价抑制剂。
公司简介
公司代码BMEA
公司名称Biomea Fusion Inc
上市日期Apr 16, 2021
CEODr. Michael J.M. (Mick) Hitchcock, Ph.D.
员工数量106
证券类型Ordinary Share
年结日Apr 16
公司地址1599 Industrial Road
城市SAN CARLOS
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94070
电话16509809099
网址https://www.biomeafusion.com/
公司代码BMEA
上市日期Apr 16, 2021
CEODr. Michael J.M. (Mick) Hitchcock, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.53M
--
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
,
,
Senior Director, Investor Relations and Corporate Development
Senior Director, Investor Relations and Corporate Development
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.53M
--
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 6月27日 周五
更新时间: 6月27日 周五
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
9.53%
Heights Capital Management, Inc.
7.80%
Cormorant Asset Management, LP
6.26%
Butler (Thomas Andrew)
5.22%
Erdtmann (Rainer M)
4.44%
Other
66.74%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
9.53%
Heights Capital Management, Inc.
7.80%
Cormorant Asset Management, LP
6.26%
Butler (Thomas Andrew)
5.22%
Erdtmann (Rainer M)
4.44%
Other
66.74%
股东类型
持股股东
占比
Investment Advisor
25.05%
Hedge Fund
11.10%
Individual Investor
9.95%
Investment Advisor/Hedge Fund
7.02%
Research Firm
1.11%
Bank and Trust
0.31%
Family Office
0.10%
Pension Fund
0.03%
Other
45.33%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
269
31.12M
54.57%
-2.04M
2025Q1
286
30.27M
56.89%
-6.92M
2024Q4
291
32.11M
88.62%
-5.43M
2024Q3
283
32.46M
89.61%
-9.72M
2024Q2
276
32.63M
90.57%
-17.02M
2024Q1
262
40.47M
112.52%
-6.23M
2023Q4
249
37.13M
103.84%
-10.53M
2023Q3
227
38.85M
108.96%
-7.82M
2023Q2
225
38.32M
108.02%
-4.44M
2023Q1
192
32.77M
97.40%
+4.19M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
5.44M
9.53%
--
--
Mar 31, 2025
Heights Capital Management, Inc.
4.45M
7.8%
+4.45M
--
Jun 17, 2025
Cormorant Asset Management, LP
3.57M
6.26%
--
--
Mar 31, 2025
Butler (Thomas Andrew)
2.97M
5.22%
--
--
Mar 31, 2025
Erdtmann (Rainer M)
2.53M
4.44%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.96M
3.44%
-43.41K
-2.16%
Mar 31, 2025
The Vanguard Group, Inc.
1.38M
2.42%
-23.05K
-1.65%
Mar 31, 2025
Two Sigma Investments, LP
963.36K
1.69%
-56.07K
-5.50%
Mar 31, 2025
Aisling Capital Management LP
798.76K
1.4%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
625.95K
1.1%
+21.81K
+3.61%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
占比0.01%
iShares Micro-Cap ETF
占比0.01%
iShares Biotechnology ETF
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0.01%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
ProShares Hedge Replication ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
iShares Morningstar Small-Cap ETF
占比0%
iShares Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
